Danaher Co. (NYSE:DHR) Shares Sold by Dorsey Asset Management LLC

Dorsey Asset Management LLC cut its position in Danaher Co. (NYSE:DHR) by 1.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 306,420 shares of the conglomerate’s stock after selling 3,944 shares during the quarter. Danaher accounts for about 9.1% of Dorsey Asset Management LLC’s holdings, making the stock its 6th biggest holding. Dorsey Asset Management LLC’s holdings in Danaher were worth $76,559,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the company. Tsfg LLC increased its position in Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares during the period. nVerses Capital LLC acquired a new stake in shares of Danaher during the second quarter worth $25,000. CarsonAllaria Wealth Management Ltd. acquired a new stake in shares of Danaher during the second quarter worth $25,000. Cape Investment Advisory Inc. bought a new position in Danaher during the fourth quarter worth $25,000. Finally, Redmont Wealth Advisors LLC acquired a new position in Danaher in the first quarter valued at $30,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Trading Down 2.3 %

NYSE:DHR opened at $267.89 on Thursday. Danaher Co. has a one year low of $182.09 and a one year high of $281.70. The company has a market cap of $193.47 billion, a PE ratio of 45.41, a PEG ratio of 4.55 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The firm has a 50-day moving average of $268.61 and a 200-day moving average of $257.47.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company’s revenue for the quarter was down 2.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.05 EPS. As a group, equities research analysts expect that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a $0.27 dividend. The ex-dividend date is Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.40%. Danaher’s dividend payout ratio is currently 18.31%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Evercore ISI decreased their price target on Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Jefferies Financial Group started coverage on Danaher in a report on Monday, June 3rd. They issued a “buy” rating and a $295.00 target price for the company. Stifel Nicolaus boosted their price target on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Finally, Leerink Partners boosted their target price on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $278.94.

Insider Activity at Danaher

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the transaction, the chief financial officer now owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. The disclosure for this sale can be found here. Insiders have sold 39,659 shares of company stock valued at $11,042,433 over the last ninety days. Corporate insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.